Medicare Card, NIH-developed candidate dengue vaccine shows promise in early-stage trial
December 1st, 2013
A candidate dengue vaccine developed by scientists at the National Institutes of Health has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. The trial results appeared in the January 17 issue of the Journal of Infectious Diseases.
Related posts:
- Medicare Card, NIH launches early-stage yellow fever vaccine trial Yellow fever virus is found in tropical and subtropical, and caused an estimated 29,000 to 60,000 deaths in 2013. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus. The Phase 1 […]...
- Medicare Card, Large-scale HIV vaccine trial to launch in South Africa Medicare Card, Large-scale HIV vaccine trial to launch in South Africa...
- Medicare Card, NIH launches trial of investigational genital herpes vaccine Medicare Card, NIH launches trial of investigational genital herpes vaccine...
- Chikungunya vaccine trial begins to enroll participants An experimental vaccine to prevent chikungunya fever, a viral disease spread by certain species of mosquitoes, is being tested in a clinical trial conducted by National Institute of Allergy and Infectious Diseases (NIAID) scientists at the National Institutes of Health....
- Medicare Card, Experimental chikungunya vaccine induces robust antibody response An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult volunteers who participated in a recent early-stage clinical trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results are reported in the current issue of […]...
- Medicare Card, NIH begins testing investigational Zika vaccine in humans Medicare Card, NIH begins testing investigational Zika vaccine in humans...
- Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins Medicare Card, Testing of investigational inactivated Zika vaccine in humans begins...
- Medicare Card, NIH-funded trial launched to assess experimental TB drug Medicare Card, NIH-funded trial launched to assess experimental TB drug...
- Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year Medicare Card, Investigational malaria vaccine protects healthy U.S. adults for more than one year...
- Possible clues found to why HIV vaccine showed modest protection Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial, those who produced relatively high levels of a […]...
- Study named 2011 Breakthrough of the Year by Science The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year....
- Priming with DNA vaccine makes avian flu vaccine work better The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say. Their report describes results from two clinical studies conducted by researchers from the National Institute of Allergy and Infectious Diseases (NIAID), […]...
- Medicare, Funded HIV clinical research sites to join pediatric tuberculosis vaccine study Several U.S. government-funded HIV/AIDS clinical research sites in Africa will join other collaborators in an ongoing clinical trial testing an investigational tuberculosis (TB) vaccine in infants at risk for TB infection. “We are pleased to be able to tap into our existing HIV/AIDS clinical research infrastructure to help test promising investigational vaccines against TB,” said […]...
- Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease Medicare Card, NIH launches largest clinical trial focused on HIV-related cardiovascular disease...
- Medicare Card, Peanut allergy prevention strategy is nutritionally safe, NIH-funded study shows Medicare Card, Peanut allergy prevention strategy is nutritionally safe, NIH-funded study shows...
Posted in MedicareCard Replacement | Tags: MEDICARE CARD